Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis Pharmaceuticals |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00413413 |
This study will evaluate the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Valsartan/amlodipine 80/5 mg Drug: Valsartan 80 mg Drug: Valsartan 160 mg |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Double Dummy, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5mg to Valsartan 160mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160mg Monotherapy. |
Enrollment: | 919 |
Study Start Date: | January 2007 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Valsartan 80 mg: Active Comparator |
Drug: Valsartan 80 mg
Valsartan 80 mg capsules (and matching placebo) for oral administration, once daily in the morning.
|
Valsartan 160 mg: Active Comparator |
Drug: Valsartan 160 mg
Valsartan 160 mg capsules (and matching placebo) for oral administration, once daily in the morning.
|
Valsartan/amlodipine 80/5 mg: Experimental |
Drug: Valsartan/amlodipine 80/5 mg
Valsartan/amlodipine 80/5 mg tablets (and matching placebo) for oral administration, once daily in the morning.
|
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
China | |
Beijing ChaoYang Hospital, Affiliate of Capital University of Medical Sciences | |
Beijing, China, 100020 | |
Beijing General Hospital of Beijing Military Region | |
Beijing, China, 100700 | |
Beijing Hospital | |
Beijing, China, 100730 | |
The people's Hospital of Liaoning Province | |
Shenyang, China, 110016 | |
The First Affiliated Hospital of China Medical University | |
Shenyang, China, 110001 | |
Second Hospital of Hebei University of Medical Sciences | |
Shijiazhuang, China, 050050 | |
The People's Hospital of Hebei Provincial | |
Shijiazhuang, China, 050051 | |
Second Military Medical University Affiliated Changzheng Hospital | |
Shanghai, China, 200003 | |
Second Military Medical University Affiliated Changhai Hospital | |
Shanghai, China, 200433 | |
Fudan University affiliated zhongshan hospital | |
Shanghai, China, 200032 | |
The First Affiliated Hospital of Nanjing Medical University | |
Nanjing, China, 210029 | |
The First Affiliated Hospital of Soochow University | |
Suzhou, China, 215006 | |
The Second Affiliated Hospital of Soochow University | |
Suzhou, China, 215004 | |
The First Affiliated Hospital of Medical College of Zhejiang University | |
Hangzhou, China, 310007 | |
The Second Affiliated Hospital of Medical College of Zhejiang University | |
Hangzhou, China, 310006 | |
The First People's Hospital of Hangzhou | |
Hangzhou, China, 310006 | |
Department of cardiology, Ruijin hospital; | |
Shanghai, China, 200025 | |
Department of cardiology, Ruijin hospital | |
Shanghai, China, 200025 | |
Southeast University Affiliated Zhong Da Hospital | |
Nanjing, China, 210009 |
Study Director: | Novartis Pharmaceuticals | Sponsor GmbH |
Responsible Party: | Novartis Pharmaceuticals ( External Affairs ) |
Study ID Numbers: | CVAA489A2316 |
Study First Received: | December 18, 2006 |
Last Updated: | November 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00413413 |
Health Authority: | China: State Food and Drug Administration; United States: Food and Drug Administration |
Hypertension, valsartan, amlodipine, high blood pressure |
Calcium, Dietary Vascular Diseases Essential hypertension |
Valsartan Amlodipine Hypertension |
Membrane Transport Modulators Vasodilator Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Calcium Channel Blockers |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |